US biotech licenses antibody from Takeda for new kidney drugs

04-10-2019

Rory O'Neill

US biotech licenses antibody from Takeda for new kidney drugs

Jonathan Weiss / Shutterstock.com

Goldfinch Bio, a US company focused on developing treatments for kidney disease, has agreed to license a cannabinoid receptor 1 (CB1) antibody from Japanese pharmaceutical manufacturer Takeda.


Goldfinch Bio, cannabinoid, receptor, CB1, kidney disease, Takeda, licence, antibody

LSIPR